PROF.DR.V.SHRUTHI KAMAL. INCIDENCE GLOBAL STATISTICS 640600 MEN 349000 WOMEN 50% adavanced carcinoma...
Preview:
Citation preview
- Slide 1
- PROF.DR.V.SHRUTHI KAMAL
- Slide 2
- INCIDENCE GLOBAL STATISTICS 640600 MEN 349000 WOMEN 50%
adavanced carcinoma CA CANCER J.CLIN 2011
- Slide 3
- Distal cancer Increase in proximal cancers Incidence remains
high in Japan Their cure rates better due to screening/
survellance/early detection
- Slide 4
- Age Average age of onset 55 yrs
- Slide 5
- Etiology Diffuse cancer Proximal & hereditary Intestinal
type Distal cancers younger Endemic/ inflammatory changes with
Helicobacter pylori infection
- Slide 6
- DIET Linked to High ingestion of
Redmeat/cabbage/spices/fish/smoked Salt preserved/high carohydrates
Low ingestion of fruits vegetables Fat /protein/vitamins A,C,E
- Slide 7
- Gastric Cancer Dietary/Lifestyle Factors Carl-McGrath S, et al.
Cancer Therapy (2007).
- Slide 8
- Helicobacter pylori infection Increased risk HP organism found
in 89% intestinal type/32% with diffuse type Trials in eradicating
HP infection
- Slide 9
- Heredity & Race African/Asian/Hispanic American >risk
Whites< risk
- Slide 10
- Anemia pernicious anemia 3to18 times > risk Achlorhydria
Atrophic gastritis
- Slide 11
- Previous Gastric resection Gastric stump ca > 15 to 20 yrs
Alakaline bile/dysplasia of gastric ca/ elevated gastrin levels
> carry poor prognosis
- Slide 12
- Mucosal dysplasia Grade I to III High grade dysplasia
>marker for future gas.ca Intestinal metaplasia/ replacement of
Glandular epithelium> intestinal type
- Slide 13
- Gastric Cancer Correa Sequence- pathophysiology Vogelgram of
CRC http://www.hopkinscoloncancercenter.org Increasing risk Normal
Chronic gastritis Mucosal atrophy Intestinal metaplasi a
Intestinal-type carcinoma Dysplasia Potentially reversible Not HGD
Hartgrink HH, et al. Lancet (2009).
- Slide 14
- Gastric polyps FAP ( Familial adenomatous polyposis) Have >
incidence of gas.ca/advised endoscopy/ survellence Hyper
plastic>do not have malig.potential
- Slide 15
- Chronic gastritis Atrophic gastritis( autoimmune) Hypertrophic
gastritis Menetriers
- Slide 16
- Other risk factors > 50 yrs Blood group A Lower socio
economic status Alcohol Smoking Obesity
- Slide 17
- Histology Adeno ca >95% Leiomyo sarcoma Lymphomas Squamous
ca >5% Carcinoid
- Slide 18
- Other risk factors contd E cadheringene mutation HNPCC
LIFraumen EB virus
- Slide 19
- Pathology Gross types> cauliflower ulcerative Leather
botttle (linitis plastica)
- Slide 20
- Laurens Intestinal type(53%) Good prognosis HP infection
Diffuse type(33%) Bld group A,Familial, signet ring,poor
differentiation, younger bad prognosis
- Slide 21
- Japanese classification Early gastric > mucosa+ submucosa+
or - nodes 1 protruded cure rate >95% 2 superdicial 3
Excavated
- Slide 22
- Slide 23
- Advanced gastric ca Muscularis+serosa + or nodes Borrmans
classification I single polypoid II ulcerated ca + clear margin
III,,,,,, + with out clear margin IV diffuse & V
unclassified
- Slide 24
- Slide 25
- MINGS classification Expanding Infiltrative
- Slide 26
- WHO Histological( Microscopic) Adeno ca>papillary,tubular
mucinous,signet Adenosuamous Squamous undifferentited
- Slide 27
- Siewert classifiaction Proximal gas.ca TypeI Ca of GE (
Barrets) TypeII With in 2 cms Squamo columnar junc TypeIII
Subcardial
- Slide 28
- Location of cancers Distal >40% Proximal>35%
Body>25%
- Slide 29
- Spread Local Ulcerative> gsatric wall> serosa
schirrous>submucosa/muscularis Lymphatic Virchows node ( left
supraclavicular ) Left axillary (Irish node) Blood spread>liver
40%Lung 40% Sclerotic bone mets/carcinomatous meningitis
- Slide 30
- contd Peritoneum 10% seedling of peritoneal surfaces
Umbilicus/falciform(sis Mary joseph nodule) Krukenberg>mets to
ovary Blumer shelf ( rectal shelf in men)
- Slide 31
- Paraneoplastic syndrome Polymyosistis Dementia Venous
thrombosis Ectopic cushing Leser Trelat sign( seborheic keratosis)
Acanthosis
- Slide 32
- Diagnosis Anorexia/early satiety/dyspepsia Dyspagia/weakness/
Abdominal pain>60% Weight loss>50% Nausea vomiting>40%
Palpable mass>30% Haemetemis/ malena>25%
- Slide 33
- Investigations CBC/LFT/Chest x-ray EGD(
esophagogastroduodenoscopy) USG/EUS(endo ultrasound) CT Diagnostic
lap
- Slide 34
- Staging TNM Tx cant be assessed T0 No eveidence of tumour Tis
in situ T1 lamina propria or submucosa T2 a muscularis propria T2
binvades subserosa T3 invades serosa T4 adjacent structure
- Slide 35
- Gastric Cancer Staging Systems TNM: most important clinical
prognostic factor http://www.hopkins- gi.org
http://www.medscape.com/viewarticle/543068_3
- Slide 36
- Nodes Nx cant be assessed No no nodes N1 1-6 nodes N2 7-15
nodes N3 > 15 nodes
- Slide 37
- Meatastasis Mx Mets cant be assessed Mo No mets M1 distant
mets
- Slide 38
- Management Surgery > Curative 1 Endoscopic mucosal resection
2 Subtotal gastrectomy distal 2cm & proximal 5 cm
clearance(Billroth II) 3 Total gastrectomy (Roux en y)
- Slide 39
- Inoperable tumours Multiple mets liver Extensive invovolment
adjacent organs SMV/SMA Carcinomatosis peritonei
- Slide 40
- Resection R0 resection > No residual disease R1
>microscopic residual disease R2> Macroscopic residual
disease R3> unresectable
- Slide 41
- Nodal stations First tier nodes 1-6 nodes Second tier nodes
7-11 nodes Third tier nodes 12-18 nodes D1 dissection nodes are N0
(3-6) D2 dissection(N1) 1-11 removed D3dissection(N2)paraaortic
hepatodudenal D4 1-18 stations
- Slide 42
- Surgery -contd Palliation Palliative resection Palliative by
pass Anterior Gastrojejunostomy/feeding jejunostomy Laser ablation/
stenting Pain relief
- Slide 43
- Chemotherapy Adjuvant chemo therapy 5 FU225mg/m2/days 1-5/1-21
Epirubicin50mg/m2 day1 Cisplatin 60mg/m2/day1
- Slide 44
- Chemo for advanced ca ECF epirubicin/5 FU/Doxorubicin EOX
epirubicin/0xaliplatin/capecitabine DCF
Docetaxel/cisplatin/5FU
- Slide 45
- Radio therapy-Role Helpful in palliation for unrsectable
tumors(4000cgy 4wks) IORT (tumour bed)
- Slide 46
- Prognosis Early 5 yr survival 70- 90% Advanced ca less than 20%
Recurrence with in 3 yrs
- Slide 47
- Gastric lymphoma Primary- elderly/NHL-B cell type Mucosal
associated lymphoid tissue (MALTOMA)/H.pylori Loss of appetite/pain
abdomen/wt loss Mass abdomen Associated SLE/HIV/Ch gastritis
etc
- Slide 48
- complications Obstruction Perforation Bleeding metastasis
- Slide 49
- treatment Treat HP infection Surgery for obstruction Chemo same
as NHL
- Slide 50
- GIST-gastroinestinal stromal tumor Non epithelial /equal sex
incidence 50-70 yrs Arises from interstitial cell of cajal Treat
surgery Chemo sunitinib imatinib
- Slide 51
- Slide 52
- THANK YOU